Multi-tract multi-symptom relationships in pediatric concussion

  1. Guido I Guberman  Is a corresponding author
  2. Sonja Stojanovski
  3. Eman Nishat
  4. Alain Ptito
  5. Danilo Bzdok
  6. Anne L Wheeler
  7. Maxime Descoteaux
  1. McGill University, Canada
  2. University of Toronto, Canada
  3. Université de Sherbrooke, Canada

Abstract

Background: The heterogeneity of white matter damage and symptoms in concussion has been identified as a major obstacle to therapeutic innovation. In contrast, most diffusion MRI (dMRI) studies on concussion have traditionally relied on group-comparison approaches that average out heterogeneity. To leverage, rather than average out, concussion heterogeneity, we combined dMRI and multivariate statistics to characterize multi-tract multi-symptom relationships.

Methods: Using cross-sectional data from 306 previously-concussed children aged 9-10 from the Adolescent Brain Cognitive Development Study, we built connectomes weighted by classical and emerging diffusion measures. These measures were combined into two informative indices, the first representing microstructural complexity, the second representing axonal density. We deployed pattern-learning algorithms to jointly decompose these connectivity features and 19 symptom measures.

Results: Early multi-tract multi-symptom pairs explained the most covariance and represented broad symptom categories, such as a general problems pair, or a pair representing all cognitive symptoms, and implicated more distributed networks of white matter tracts. Further pairs represented more specific symptom combinations, such as a pair representing attention problems exclusively, and were associated with more localized white matter abnormalities. Symptom representation was not systematically related to tract representation across pairs. Sleep problems were implicated across most pairs, but were related to different connections across these pairs. Expression of multi-tract features was not driven by sociodemographic and injury-related variables, as well as by clinical subgroups defined by the presence of ADHD. Analyses performed on a replication dataset showed consistent results.

Conclusions: Using a double-multivariate approach, we identified clinically-informative, cross-demographic multi-tract multi-symptom relationships. These results suggest that rather than clear one-to-one symptom-connectivity disturbances, concussions may be characterized by subtypes of symptom/connectivity relationships. The symptom/connectivity relationships identified in multi-tract multi-symptom pairs were not apparent in single-tract/single-symptom analyses. Future studies aiming to better understand connectivity/symptom relationships should take into account multi-tract multi-symptom heterogeneity.

Funding: financial support for this work from a Vanier Canada Graduate Scholarship from the Canadian Institutes of Health Research (GIG), an Ontario Graduate Scholarship (SS), a Restracomp Research Fellowship provided by the Hospital for Sick Children (SS), an Institutional Research Chair in Neuroinformatics (MD), as well as a Natural Sciences and Engineering Research Council CREATE grant (MD).

Data availability

All data used in this project were obtained from the Adolescent Brain Cognitive Development Study. This dataset is administered by the National Institutes of Mental Health Data Archive and is freely available to all qualified researchers upon submission of an access request. All relevant instructions to obtain the data can be found in https://nda.nih.gov/abcd/request-access. The Institutional Review Board of the McGill University Faculty of Medicine and Health Sciences reviewed the application and confirmed that no further ethics approvals were required.

The following previously published data sets were used

Article and author information

Author details

  1. Guido I Guberman

    Department of Neurology and Neurosurgery, McGill University, Montreal, Canada
    For correspondence
    guido.guberman@mail.mcgill.ca
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4422-2225
  2. Sonja Stojanovski

    Department of Physiology, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  3. Eman Nishat

    Department of Physiology, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  4. Alain Ptito

    Department of Neurology and Neurosurgery, McGill University, Montreal, Canada
    Competing interests
    No competing interests declared.
  5. Danilo Bzdok

    Montreal Neurological Institute (MNI), McGill University, Montreal, Canada
    Competing interests
    No competing interests declared.
  6. Anne L Wheeler

    Department of Physiology, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  7. Maxime Descoteaux

    Department of Computer Science, Université de Sherbrooke, Sherbrooke, Canada
    Competing interests
    Maxime Descoteaux, works as Chief Scientific Officer for IMEKA. He holds the following patents: DETERMINATION OF WHITE-MATTER NEURODEGENERATIVE DISEASE BIOMARKERS (Patent Application No.: 63/222,914), PROCESSING OF TRACTOGRAPHY RESULTS USING AN AUTOENCODER (Patent Application No.: 17/337,413). No other authors have any financial or other conflicts of interest..

Funding

Canadian Institutes of Health Research (Vanier Canada Graduate Scholarship)

  • Guido I Guberman

Government of Ontario (Ontario Graduate Scholarship)

  • Sonja Stojanovski

Hospital for Sick Children (Restracomp Research Fellowship)

  • Sonja Stojanovski

Université de Sherbrooke (Institutional Research Chair)

  • Maxime Descoteaux

Natural Sciences and Engineering Research Council of Canada (CREATE Grant)

  • Maxime Descoteaux

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The data used in this study were obtained from the Adolescent Brain Cognitive Development Study. All aspects related to ethical standards were managed by the ABCD Study team. The Institutional Review Board of the McGill University Faculty of Medicine and Health Sciences reviewed the application and confirmed that no further ethics approvals were required.

Copyright

© 2022, Guberman et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,223
    views
  • 202
    downloads
  • 7
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Guido I Guberman
  2. Sonja Stojanovski
  3. Eman Nishat
  4. Alain Ptito
  5. Danilo Bzdok
  6. Anne L Wheeler
  7. Maxime Descoteaux
(2022)
Multi-tract multi-symptom relationships in pediatric concussion
eLife 11:e70450.
https://doi.org/10.7554/eLife.70450

Share this article

https://doi.org/10.7554/eLife.70450

Further reading

    1. Cancer Biology
    2. Medicine
    Anastasia D Komarova, Snezhana D Sinyushkina ... Marina V Shirmanova
    Research Article

    Heterogeneity of tumor metabolism is an important, but still poorly understood aspect of tumor biology. Present work is focused on the visualization and quantification of cellular metabolic heterogeneity of colorectal cancer using fluorescence lifetime imaging (FLIM) of redox cofactor NAD(P)H. FLIM-microscopy of NAD(P)H was performed in vitro in four cancer cell lines (HT29, HCT116, CaCo2 and CT26), in vivo in the four types of colorectal tumors in mice and ex vivo in patients’ tumor samples. The dispersion and bimodality of the decay parameters were evaluated to quantify the intercellular metabolic heterogeneity. Our results demonstrate that patients’ colorectal tumors have significantly higher heterogeneity of energy metabolism compared with cultured cells and tumor xenografts, which was displayed as a wider and frequently bimodal distribution of a contribution of a free (glycolytic) fraction of NAD(P)H within a sample. Among patients’ tumors, the dispersion was larger in the high-grade and early stage ones, without, however, any association with bimodality. These results indicate that cell-level metabolic heterogeneity assessed from NAD(P)H FLIM has a potential to become a clinical prognostic factor.

    1. Medicine
    Sindre Lee-Ødegård, Marit Hjorth ... Kåre Inge Birkeland
    Research Article

    Background:

    Physical activity has been associated with preventing the development of type 2 diabetes and atherosclerotic cardiovascular disease. However, our understanding of the precise molecular mechanisms underlying these effects remains incomplete and good biomarkers to objectively assess physical activity are lacking.

    Methods:

    We analyzed 3072 serum proteins in 26 men, normal weight or overweight, undergoing 12 weeks of a combined strength and endurance exercise intervention. We estimated insulin sensitivity with hyperinsulinemic euglycemic clamp, maximum oxygen uptake, muscle strength, and used MRI/MRS to evaluate body composition and organ fat depots. Muscle and subcutaneous adipose tissue biopsies were used for mRNA sequencing. Additional association analyses were performed in samples from up to 47,747 individuals in the UK Biobank, as well as using two-sample Mendelian randomization and mice models.

    Results:

    Following 12 weeks of exercise intervention, we observed significant changes in 283 serum proteins. Notably, 66 of these proteins were elevated in overweight men and positively associated with liver fat before the exercise regimen, but were normalized after exercise. Furthermore, for 19.7 and 12.1% of the exercise-responsive proteins, corresponding changes in mRNA expression levels in muscle and fat, respectively, were shown. The protein CD300LG displayed consistent alterations in blood, muscle, and fat. Serum CD300LG exhibited positive associations with insulin sensitivity, and to angiogenesis-related gene expression in both muscle and fat. Furthermore, serum CD300LG was positively associated with physical activity and negatively associated with glucose levels in the UK Biobank. In this sample, the association between serum CD300LG and physical activity was significantly stronger in men than in women. Mendelian randomization analysis suggested potential causal relationships between levels of serum CD300LG and fasting glucose, 2 hr glucose after an oral glucose tolerance test, and HbA1c. Additionally, Cd300lg responded to exercise in a mouse model, and we observed signs of impaired glucose tolerance in male, but not female, Cd300lg knockout mice.

    Conclusions:

    Our study identified several novel proteins in serum whose levels change in response to prolonged exercise and were significantly associated with body composition, liver fat, and glucose homeostasis. Serum CD300LG increased with physical activity and is a potential causal link to improved glucose levels. CD300LG may be a promising exercise biomarker and a therapeutic target in type 2 diabetes.

    Funding:

    South-Eastern Norway Regional Health Authority, Simon Fougners Fund, Diabetesforbundet, Johan Selmer Kvanes’ legat til forskning og bekjempelse av sukkersyke. The UK Biobank resource reference 53641. Australian National Health and Medical Research Council Investigator Grant (APP2017942). Australian Research Council Discovery Early Career Award (DE220101226). Research Council of Norway (Project grant: 325640 and Mobility grant: 287198). The Medical Student Research Program at the University of Oslo. Novo Nordisk Fonden Excellence Emerging Grant in Endocrinology and Metabolism 2023 (NNF23OC0082123).

    Clinical trial number:

    clinicaltrials.gov: NCT01803568.